Articles
A New Concept and New Criteria for Alzheimer's Disease
This two-step procedure, which relies on the Diagnostic and Statistic Manual of Mental Disorders IV Text Revision (DSM-IV-TR) and the National...
A Pathophysiological Role for Selective Alteration of the Cytokine–Chemokine Network—Inflammatory Theory in Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia, and worldwide affects 20–30 million individuals over 60 years of age. In 1907 Alois...
A Review of the First Transdermal Treatment for Alzheimer’s Disease – The Rivastigmine Patch
Currently, cholinesterase inhibitors are the mainstay in clinical practice of symptomatic treatment for Alzheimer’s disease (AD). They are believed...
A Year in Neurology
Multiple Sclerosis In multiple sclerosis (MS), 2008 has been a big year in terms of diseasemodifying therapies. Results from key clinical trials...
Advances in Our Understanding of the Pathophysiology of Alzheimer's Disease
Alzheimer’s disease (AD) is a neurodegenerative age-related progressive disease and the most common cause of dementia in the elderly.1 Current...
Alzheimer's Disease Therapeutics
This delay in recognition of AD as a major neurological disease of aging does not reflect its impact.There are the personal tragedies that accompany...
Alzheimer’s Disease and Adult Neurogenesis—Are Endogenous Stem Cells Part of the Solution?
Numerous clinical trials are under way to evaluate therapeutic approaches to stop the progression of Alzheimer’s disease (AD). Despite the...
Alzheimer’s Disease – The Importance of Early Detection
In the UK alone, the total cost of care for late-onset dementia in 2005–2006 is estimated at £17.03 billion (€21.88 billion; US$29.89 billion),...
Amyloid Precursor Protein Neurotrophic Properties As a Target to Cure Alzheimer's Disease
Furthermore, in most studies, the role of tau has been understated for a long time. To apprehend this role, the Inserm team has developed a...
Are Biomarkers Valid as Surrogates for Treatment Effects in Alzheimer’s Disease?
Alzheimer’s disease (AD) is a complex, heterogeneous age-related disorder and the most common form of dementia. It is characterised clinically by a...
As Use of Herbal Remedies Soars, Patients Taking These and Cardiovascular Medications May be at Heightened Risk of Dangerous, Potentially Life-Threatening Interactions
"Many people have a false sense of security about these herbal products because they are seen as 'natural,'" said Arshad Jahangir, M.D.,...
Behavioral and Neurophysiological Characteristics of Lewy Body Dementia Implications for Intervention
Another common form of dementia is Lewy body dementia (LBD). As its name suggests, LBD is characterized by the presence of Lewy bodies—...
Biomarkers in Alzheimer’s Disease—Perspectives for the Future
There has been remarkable progress in developing biological markers (biomarkers) that provide insight into the progression of Alzheimer’s disease...
Blood Biomarkers for Alzheimer’s Disease
AD is becoming a major health problem in the developed world as life expectancy increases, and the disease affects about 15 million people worldwide...
BTG - Cutting Edge of Alzheimer's Disease Therapy
Dementia is a term used to describe acquired cognitive impairments that interfere with day-to-day functioning. In addition to describing a clinical...
BTG - Pharmacotherapy of Alzheimer's Disease - Current and Future Perspectives
Natural History of Alzheimer’s Disease The natural history of AD can be broadly considered as comprising a pre-symptomatic stage during which...
Can We Propose Rational Clinical Trials for Lewy Body Dementia?
In this article, we will consider the clinical, neurochemical, and pathological features of the various types of DLB, review therapeutic strategies...
Chronic Stress Accelerates and Intensifies Aβ-induced Alzheimer’s-disease-like Pathogenesis in Rat Models
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by extracellular deposition of pathogenic amyloid-beta (Aβ)...
Clinical Experience of Memantine in Alzheimer’s Disease
There is a wide variation in the rate of disease progression in patients with AD, although cognitive deterioration is always persistent and...
Clinical Heterogeneity Associated with Tau Gene Mutations
With the description of more MAPT mutations, the clinical and neuropathological heterogeneity of FTDP-17 cases has become increasingly apparent. An...
